bims-livmat Biomed News
on Living materials
Issue of 2026–02–08
six papers selected by
Sara Trujillo Muñoz, Leibniz-Institut für Neue Materialien



  1. bioRxiv. 2026 Jan 21. pii: 2026.01.16.699961. [Epub ahead of print]
      Chronic exposure to inorganic arsenic remains a major global health concern, as arsenite is frequently present in contaminated food and drinking water and readily absorbed through the gastrointestinal (GI) tract. Once internalized, arsenite accumulates in tissues and contributes to long-term health effects, including cancer, organ dysfunction, and neurological disorders. Despite extensive efforts to reduce environmental contamination, there are currently no practical strategies to prevent dietary arsenite from entering the human body during digestion. Here, we report a synthetic biology-based approach that uses engineered probiotics to detect and sequester arsenite directly within the GI tract before systemic absorption occurs. We engineered Escherichia coli Nissle 1917 (EcN), a probiotic strain, to function as a living arsenite-interception system. Central to this design is an arsenite-responsive genetic toggle switch that activates chelator expression upon exposure and sustains production under biostatic conditions, while automatically shutting off during active cell division to limit metabolic burden and enhance biosafety. In parallel, we engineered an arsenite-binding protein derived from the transcriptional regulator ArsR to eliminate DNA-binding activity while retaining high-affinity metal binding, yielding a non-toxic chelator suitable for intracellular sequestration. The resulting engineered strain efficiently removed arsenite from its surrounding environment in vitro while maintaining robust cell viability and growth. To translate these findings to an in vivo context, we developed a mass-transfer model describing arsenite distribution among the stomach lumen, engineered bacteria, and epithelial cells. This model guided the selection of a bacterial dose predicted to substantially deplete lumenal arsenite prior to epithelial uptake. Using this strategy, we demonstrated in a mouse GI model that oral administration of engineered EcN markedly reduced arsenite entry into the bloodstream compared with wild-type EcN or no-bacteria controls. Together, these results establish a programmable probiotic platform for intercepting dietary arsenite and highlight a potential strategy for preventing absorption of environmental toxicants using living microbial therapeutics.
    DOI:  https://doi.org/10.64898/2026.01.16.699961
  2. ACS Synth Biol. 2026 Feb 02.
      Dopamine deficiency resulting from nigrostriatal dopaminergic neuronal damage manifests as extrapyramidal motor symptoms of Parkinson's disease (PD). Oral tablet dosing of levodopa, administered 3-4 times a day, remains the standard of care due to its tolerability and effectiveness; however, it is prone to deleterious side effects, including off-periods and levodopa-induced dyskinesia after long-term use. Herein, using synthetic biology approaches, we developed and systematically evaluated the feasibility of a probiotic-based live-biotherapeutic system to continuously deliver L-DOPA stably, thereby relieving motor symptoms. Our data demonstrate that our engineered plasmid-based L-DOPA-expressing Escherichia coli Nissle 1917 probiotic strain (EcN2LDOPA-P3) efficiently produced up to 12,000 ng/mL L-DOPA in vitro. In mouse model systems, EcN2LDOPA-P3 readily colonized for up to 48 h, achieved steady-state plasma L-DOPA concentrations, and increased brain L-DOPA and dopamine levels by 1- to 2-fold. Lastly, EcN2LDOPA-P3 significantly diminished motor and nonmotor behavioral deficits in a mouse model of PD compared to traditional chemical L-DOPA therapy. These findings support the therapeutic feasibility of a noninvasive, orally administered bioengineered bacterial therapy for the chronic delivery of L-DOPA, which may address limitations associated with current treatment alternatives.
    Keywords:  Escherichia coli Nissle 1917; L-DOPA; Parkinson’s disease; live-biotherapeutic; metabolic engineering; microbiome
    DOI:  https://doi.org/10.1021/acssynbio.5c00786
  3. J Control Release. 2026 Jan 28. pii: S0168-3659(26)00067-2. [Epub ahead of print]392 114666
      The clinical potential of oral genetically engineered probiotics is widely recognized, which is usually distinguished by the release of expressed active molecules. However, the impact of the release mode of bacterial payloads remains unknown. Here, we propose a novel release mode, "producing and storing first, then responding and releasing", in a genetically engineered probiotic. Inflammatory bowel disease is a typical chronic intestinal disease, where nitrate in the intestinal route is highly produced. Escherichia coli Nissle 1917 (EcN) was genetically engineered to highly express TNF-α nanobodies (NbTNF-α) for storing and releasing in response to nitrate. Two types of release systems were designed: a protein complex secretion machine, Hly system, and a φX174E-based lysis-release system. These systems were separately recombined into EcN as E5 and E7. The expression and strong anti-inflammation activity of NbTNF-α from E. coli were first confirmed. A NarX/L sensing system was tailored for nitrate, which was a typical biomarker of intestinal inflammation. Both E5 and E7 exhibited similar in vitro kinetics of NbTNF-α secretion. High anti-ulcerative colitis effects were achieved by oral administration of E5 and E7, characterized by inflammation attenuation and recovery of intestinal mucosal barriers, and the levels of NbTNF-α expressed by both in the intestinal tract were similar. This work provides new insights into the design of pathological environment-responsive genetically engineered probiotics against diseases.
    Keywords:  Genetic engineering; Inflammatory bowel disease; Nanobody; Nitrate; Probiotic
    DOI:  https://doi.org/10.1016/j.jconrel.2026.114666
  4. World J Microbiol Biotechnol. 2026 Jan 31. 42(2): 69
      Bacterial ghosts (BGs) are an emerging vaccine platform produced by completely removing the cytoplasmic contents of bacterial cells while preserving their native surface architecture. This unique structural integrity enables BGs to function simultaneously as safe, non-living vaccines and efficient delivery vehicles. Recent advances in both genetic (phage lysis gene E) and chemical "sponge-like" protocols have expanded the range of microorganisms from which BGs can be produced, improving safety, scalability, and antigenic stability. This review summarizes current progress in BG technology with a focus on their innovative applications as antibacterial, antifungal, and anticancer vaccines; adjuvants; and carriers for DNA, proteins, and bioactive molecules. Particular emphasis is placed on emerging directions such as yeast and fungal ghosts, novel characterization methods, and the development of BG-based nano-vaccines. Future prospects highlight the need for standardized production, improved clinical translation, and comparative evaluation with related platforms such as membrane vesicles. Together, these advancements position BGs as a promising next-generation vaccine and drug-delivery strategy with significant potential for translational impact.
    Keywords:  Bacterial ghosts (BGs); Gene E-mediated lysis; Immunotherapy; Vaccine platform; Vaccines
    DOI:  https://doi.org/10.1007/s11274-026-04783-7
  5. Front Microbiol. 2025 ;16 1742486
       Introduction: Lactiplantibacillus plantarum (L. plantarum) has been reported to attenuate ulcerative colitis (UC) and restore intestinal barrier integrity. However, it remains unclear whether culture supernatant or extracellular vesicles (EVs) are more effective.
    Methods: UC was induced in mice to compare the effects of L. plantarum 25 (LP25) supernatant and EVs on disease severity, survival, and tight junction protein expression. Gut microbiota and metabolism were analyzed by 16S rRNA sequencing and untargeted metabolomics. In vitro, LPS-stimulated Caco-2 cells and a Caco-2/RAW 264.7 co-culture model were used to evaluate barrier integrity, immune responses, and TLR4/NF-κB pathway activation.
    Results: Compared with EVs, LP25 supernatant significantly improved survival, alleviated disease severity, preserved tight junction protein expression, modulated gut microbiota, enhanced intestinal functional protein expression, and inhibited macrophage TLR4/NF-κB activation.
    Discussion: LP25 supernatant exerts superior protective effects compared with EVs in alleviating UC and maintaining intestinal barrier function, highlighting its potential as a functional component for dietary interventions targeting inflammatory bowel diseases.
    Keywords:  Lactiplantibacillus plantarum; extracellular vesicles; intestinal microbiota; tight junction protein; ulcerative colitis
    DOI:  https://doi.org/10.3389/fmicb.2025.1742486
  6. Nat Commun. 2026 Feb 02.
      Plasmids remain by far the most common medium for delivering engineered DNA to microorganisms. However, the reliance on natural plasmid replication mechanisms limits their tunability, compatibility, and modularity. Here we refactored the natural pMB1 origin and created plasmids with customizable copy numbers by tuning refactored components. We then created compatible origins that use synthetic RNA regulators to implement independent copy control. We further demonstrated that the synthetic origin of replication (SynORI) can be engineered modularly to respond to various signals, allowing for multiplexed copy-based reporting of environmental signals. Lastly, a library of 6 compatible SynORI plasmids was created and co-maintained in E. coli for a week. This work establishes the feasibility of creating plasmids with SynORI that can serve as a biotechnology for synthetic biology.
    DOI:  https://doi.org/10.1038/s41467-026-68907-1